Blog

- Andrew Celentano

A ‘universal’ therapy against the seasonal flu? Antibody cocktail targets virus weak spot

An unusual therapy developed at The Jackson Laboratory (JAX) could change the way the world fights influenza, one of the deadliest infectious diseases. In a new study in Science Advances, researchers report that a cocktail of antibodies protected mice—including those with weakened immune systems—from nearly every strain of influenza tested, including avian and swine variants that pose pandemic threats.

Read More »

New imaging approach simplifies retina exams by enabling digital refocusing

A team of researchers from Johns Hopkins University, Boston University, and collaborators has now demonstrated a new type of fundus camera that removes one of the main challenges: focusing. Instead of relying on mechanical adjustments of a lens, the system uses a special diffuser that captures 3D light information during imaging. With this data, a computer can reconstruct and refocus images after they are taken.

Read More »

Lupin Receives U.S. FDA Approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity

NAPLES, Fla., Sept. 10, 2025 /PRNewswire/ — Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial, and 50 mg per vial, Single-Dose Vials.

Read More »